U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H21N3O3
Molecular Weight 363.4105
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OZENOXACIN

SMILES

Cc1cc(c[nH]c1=NC)-c2ccc3c(c2C)n(cc(c3=O)C(=O)O)C4CC4

InChI

InChIKey=XPIJWUTXQAGSLK-UHFFFAOYSA-N
InChI=1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27)

HIDE SMILES / InChI

Molecular Formula C21H21N3O3
Molecular Weight 363.4105
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://www.drugs.com/history/ozenoxacin.html | https://clinicaltrials.gov/ct2/show/NCT02090764 | https://www.ncbi.nlm.nih.gov/pubmed/11864945

Ozenoxacin is an experimental quinolone antibiotic being developed for the treatment of impetigo and other dermatological bacterial infections. Ozenoxacin is active against some bacteria that have developed resistance to currently used quinolone and fluoroquinolone antibiotics. In two phase 3 studies, Ozenoxacin cream, 1%, applied topically twice daily for 5 days vs. placebo, demonstrated superiority on both clinical and bacteriological endpoints, according to the release. Superior bacteriological cure of Ozenoxacin compared to placebo was demonstrated as early as day 4. In both adults and a pediatric population aged 2 months and older, Ozenoxacin treatment was reported to be safe and well tolerated.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
XEPI

Approved Use

XEPI™ is indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older

Launch Date

1.51286396E12
Curative
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
10796 ng/mL
100 mg/kg bw 1 times / day multiple, oral
dose: 100 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OZENOXACIN plasma
Canis lupus
population: HEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
63458 ng × h/mL
100 mg/kg bw 1 times / day multiple, oral
dose: 100 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OZENOXACIN plasma
Canis lupus
population: HEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.9 h
100 mg/kg bw 1 times / day multiple, oral
dose: 100 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OZENOXACIN plasma
Canis lupus
population: HEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1 % 2 times / day multiple, topical
Recommended
Dose: 1 %, 2 times / day
Route: topical
Route: multiple
Dose: 1 %, 2 times / day
Sources: Page: 208945Orig1s000MedR.pdf - p.49 | 208945Orig1s000MedR.pdf - p.102
unhealthy, 2 months of age and above
n = 206
Health Status: unhealthy
Condition: impetigo
Age Group: 2 months of age and above
Sex: M+F
Population Size: 206
Sources: Page: 208945Orig1s000MedR.pdf - p.49 | 208945Orig1s000MedR.pdf - p.102
Disc. AE: Rosacea, Seborrheic dermatitis...
AEs leading to
discontinuation/dose reduction:
Rosacea (grade 1, 0.5%)
Seborrheic dermatitis (grade 2, 0.5%)
Skin tightness (grade 3, 0.5%)
Eczema (grade 4, 0.5%)
Sources: Page: 208945Orig1s000MedR.pdf - p.49 | 208945Orig1s000MedR.pdf - p.102
50 mg 1 times / day single, topical
Highest studied dose
Dose: 50 mg, 1 times / day
Route: topical
Route: single
Dose: 50 mg, 1 times / day
Sources:
healthy, adult
n = 8
Other AEs: Application site itching...
AEs

AEs

AESignificanceDosePopulation
Rosacea grade 1, 0.5%
Disc. AE
1 % 2 times / day multiple, topical
Recommended
Dose: 1 %, 2 times / day
Route: topical
Route: multiple
Dose: 1 %, 2 times / day
Sources: Page: 208945Orig1s000MedR.pdf - p.49 | 208945Orig1s000MedR.pdf - p.102
unhealthy, 2 months of age and above
n = 206
Health Status: unhealthy
Condition: impetigo
Age Group: 2 months of age and above
Sex: M+F
Population Size: 206
Sources: Page: 208945Orig1s000MedR.pdf - p.49 | 208945Orig1s000MedR.pdf - p.102
Seborrheic dermatitis grade 2, 0.5%
Disc. AE
1 % 2 times / day multiple, topical
Recommended
Dose: 1 %, 2 times / day
Route: topical
Route: multiple
Dose: 1 %, 2 times / day
Sources: Page: 208945Orig1s000MedR.pdf - p.49 | 208945Orig1s000MedR.pdf - p.102
unhealthy, 2 months of age and above
n = 206
Health Status: unhealthy
Condition: impetigo
Age Group: 2 months of age and above
Sex: M+F
Population Size: 206
Sources: Page: 208945Orig1s000MedR.pdf - p.49 | 208945Orig1s000MedR.pdf - p.102
Skin tightness grade 3, 0.5%
Disc. AE
1 % 2 times / day multiple, topical
Recommended
Dose: 1 %, 2 times / day
Route: topical
Route: multiple
Dose: 1 %, 2 times / day
Sources: Page: 208945Orig1s000MedR.pdf - p.49 | 208945Orig1s000MedR.pdf - p.102
unhealthy, 2 months of age and above
n = 206
Health Status: unhealthy
Condition: impetigo
Age Group: 2 months of age and above
Sex: M+F
Population Size: 206
Sources: Page: 208945Orig1s000MedR.pdf - p.49 | 208945Orig1s000MedR.pdf - p.102
Eczema grade 4, 0.5%
Disc. AE
1 % 2 times / day multiple, topical
Recommended
Dose: 1 %, 2 times / day
Route: topical
Route: multiple
Dose: 1 %, 2 times / day
Sources: Page: 208945Orig1s000MedR.pdf - p.49 | 208945Orig1s000MedR.pdf - p.102
unhealthy, 2 months of age and above
n = 206
Health Status: unhealthy
Condition: impetigo
Age Group: 2 months of age and above
Sex: M+F
Population Size: 206
Sources: Page: 208945Orig1s000MedR.pdf - p.49 | 208945Orig1s000MedR.pdf - p.102
Application site itching grade 1, 12.5%
50 mg 1 times / day single, topical
Highest studied dose
Dose: 50 mg, 1 times / day
Route: topical
Route: single
Dose: 50 mg, 1 times / day
Sources:
healthy, adult
n = 8
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​Tox targets

Tox targets

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial.
2014
Patents

Patents

Sample Use Guides

1% cream was applied topically on affected area of 1–100 cm^2 twice dally for 5 days
Route of Administration: Topical
In vitro development of resistance was carried out using a broth microdilution method by exposing bacteria to stepwise increasing concentrations of T-3912 (Ozenoxacin). Selection of drug-resistant derivatives was carried out by exposure of 5. aureus SA113 and P. ctcnes JCM6425 to stepwise increasing concentrations of T-3912. A series of microtitre wells containing two-fold serial dilutions of T-3912 was inoculated with a final concentration of 10^5 cfu/mL and then incubated for 24 h for S. aureus SA113 and for 48 h for P. acnes JCM6425. In the next step, the well with the highest T-3912 concentration still showing turbidity was used to inoculate a new series of microtitre tray. The procedure was repeated, and the MICs were determined for up to 28 passages.
Substance Class Chemical
Created
by admin
on Sat Jun 26 00:01:33 UTC 2021
Edited
by admin
on Sat Jun 26 00:01:33 UTC 2021
Record UNII
V0LH498RFO
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OZENOXACIN
INN   JAN   WHO-DD  
INN   USAN  
Official Name English
OZENOXACIN [JAN]
Common Name English
XEPI
Brand Name English
OZENOXACIN [ORANGE BOOK]
Common Name English
1-CYCLOPROPYL-8-METHYL-7-(5-METHYL-6-(METHYLAMINO)PYRIDIN-3-YL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID
Systematic Name English
OZENOXACIN [MI]
Common Name English
3-QUINOLINECARBOXYLIC ACID, 1-CYCLOPROPYL-1,4-DIHYDRO-8-METHYL-7-(5-METHYL-6-(METHYLAMINO)-3-PYRIDINYL)-4-OXO-
Systematic Name English
OZENOXACIN [USAN]
Common Name English
GF-001001-00
Code English
T-3912
Code English
OZENOXACIN [INN]
Common Name English
OZENOXACIN [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-ATC D06AX14
Created by admin on Sat Jun 26 00:01:34 UTC 2021 , Edited by admin on Sat Jun 26 00:01:34 UTC 2021
NDF-RT N0000175937
Created by admin on Sat Jun 26 00:01:34 UTC 2021 , Edited by admin on Sat Jun 26 00:01:34 UTC 2021
NCI_THESAURUS C795
Created by admin on Sat Jun 26 00:01:34 UTC 2021 , Edited by admin on Sat Jun 26 00:01:34 UTC 2021
Code System Code Type Description
FDA UNII
V0LH498RFO
Created by admin on Sat Jun 26 00:01:34 UTC 2021 , Edited by admin on Sat Jun 26 00:01:34 UTC 2021
PRIMARY
DRUG BANK
DB12924
Created by admin on Sat Jun 26 00:01:34 UTC 2021 , Edited by admin on Sat Jun 26 00:01:34 UTC 2021
PRIMARY
CAS
245765-41-7
Created by admin on Sat Jun 26 00:01:34 UTC 2021 , Edited by admin on Sat Jun 26 00:01:34 UTC 2021
PRIMARY
DRUG CENTRAL
5058
Created by admin on Sat Jun 26 00:01:34 UTC 2021 , Edited by admin on Sat Jun 26 00:01:34 UTC 2021
PRIMARY
NCI_THESAURUS
C90935
Created by admin on Sat Jun 26 00:01:34 UTC 2021 , Edited by admin on Sat Jun 26 00:01:34 UTC 2021
PRIMARY
LACTMED
Ozenoxacin
Created by admin on Sat Jun 26 00:01:34 UTC 2021 , Edited by admin on Sat Jun 26 00:01:34 UTC 2021
PRIMARY
MERCK INDEX
M11943
Created by admin on Sat Jun 26 00:01:34 UTC 2021 , Edited by admin on Sat Jun 26 00:01:34 UTC 2021
PRIMARY
RXCUI
1994739
Created by admin on Sat Jun 26 00:01:34 UTC 2021 , Edited by admin on Sat Jun 26 00:01:34 UTC 2021
PRIMARY
PUBCHEM
9863827
Created by admin on Sat Jun 26 00:01:34 UTC 2021 , Edited by admin on Sat Jun 26 00:01:34 UTC 2021
PRIMARY
INN
8788
Created by admin on Sat Jun 26 00:01:34 UTC 2021 , Edited by admin on Sat Jun 26 00:01:34 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> INHIBITOR
In vitro, ozenoxacin caused mild inhibition of CYP3A4 and CYP2C9 at high concentrations (?100 ?M).
METABOLIC ENZYME -> INHIBITOR
In vitro, ozenoxacin caused mild inhibition of CYP3A4 and CYP2C9 at high concentrations (?100 ?M).
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY